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Abstract
Background—The National Birth Defects Prevention Study (NBDPS) is a large population-
based multi-center case-control study of major birth defects in the United States.
Methods—Data collection took place from 1998 through 2013 on pregnancies ending between 
October 1997 and December 2011. Cases could be live born, stillborn or induced terminations, 
and were identified from birth defects surveillance programs in Arkansas, California, Georgia, 
Iowa, Massachusetts, New Jersey, New York, North Carolina, Texas and Utah. Controls were live 
born infants without major birth defects identified from the same geographical regions and time 
periods as cases via either vital records or birth hospitals. Computer-assisted telephone interviews 
were completed with women between 6 weeks and 24 months after the estimated date of delivery. 
After completion of interviews, families received buccal cell collection kits for the mother, father 
and infant (if living).
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Results—There were 47,832 eligible cases and 18,272 eligible controls. Among these, 32,187 
(67%) and 11,814 (65%) respectively, provided interview information about their pregnancies. 
Buccal cell collection kits with a cytobrush for at least one family member were returned by 
19,065 case and 6,211 control families (65% and 59% of those who were sent a kit). More than 
500 projects have been proposed by the collaborators and over 200 manuscripts published using 
data from the NBDPS through December 2014.
Conclusion—The NBDPS has made substantial contributions to the field of birth defects 
epidemiology through its rigorous design, including case classification, detailed questionnaire and 
specimen collection, large study population, and collaborative activities across Centers.
Major structural birth defects are common, costly and critical. About three percent of all live 
births in the United States are affected by birth defects (Centers for Disease and Prevention, 
2008); they account for one in five infant deaths (Xu and others, 2014) and contribute 
substantially to childhood morbidity and long-term disability. Most birth defects are due to 
unknown causes or a combination of causes (Nelson and Holmes, 1989), and because the 
etiologies of specific phenotypes may vary, it is important to study them in homogeneous 
groups. However, because individual types of birth defects are relatively rare, it has been 
difficult in the past to conduct a study large enough to provide the necessary statistical 
power to assess risk factors for individual defects.
In 1996, Congress appropriated funds to the U.S. Centers for Disease Control and 
Prevention (CDC) to establish the Centers for Birth Defects Research and Prevention. This 
funding was formalized by the Birth Defects Prevention Act of 1998. A Georgia Center was 
established at CDC and cooperative agreements awarded with competitive renewals to 
Centers in nine states during one or more cycles of the cooperative agreement. From 1997 to 
2013, the primary collaborative activity of these Centers was a multi-center case-control 
study, the National Birth Defects Prevention Study (NBDPS). In this manuscript, we 
summarize the methods (Figure 1) used during the data collection phase of the NBDPS.
NBDPS Centers and population
Participating Centers had access to data from a birth defects surveillance program that used 
active case-finding for all major structural birth defects eligible for inclusion in the NBDPS 
(Table 1). Since each Center was expected to contribute about 300 cases per year, the 
minimum population base was 35,000 births per year. For most years of the study, the study 
sites covered a birth population between 35,000-80,000 births per year. Participating Centers 
were Arkansas (AR, statewide), California (CA, selected counties), Georgia (GA, selected 
counties), Iowa (IA, statewide), Massachusetts (MA, selected counties except for 16 months 
when it was statewide), North Carolina (NC, selected counties), New Jersey (NJ, statewide, 
some common defects were sampled), New York (NY, selected counties), Texas (TX, 
selected counties) and Utah (UT, statewide) (Figure A online). Abstractors at each of the 
birth defects surveillance programs went out to birth and children's hospitals to ascertain 
eligible birth defects. This information was then entered in the NBDPS clinical database for 
review.
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There were changes in NBDPS Centers over time (Figure 2), NJ stopped contributing data in 
2003, and NC and UT started contributing data in 2003. Case ascertainment procedures also 
changed over time for some Centers with respect to the inclusion of cases among live births, 
stillbirths and induced abortions, and the use of data sources specifically to ascertain 
prenatal diagnoses, such as specialized ultrasound clinics (Figure 2).
Study eligibility started with pregnancies ending on or after October 1, 1997 and concluded 
with pregnancies with estimated dates of delivery (EDD) on or before December 31, 2011. 
During this study period, there were approximately six million births in the NBDPS 
catchment areas. Each Center's surveillance program ascertained all case infants with 
NBDPS-eligible birth defects that occurred in the study region. All Centers included defects 
diagnosed at least until the child turned one year old; some Centers included defects 
diagnosed up to two years old. Control infants were randomly selected from among live 
born infants from the same study region as the cases; the monthly number of controls 
selected was proportionate to the number of births in the same month in the previous year. 
Control infants were selected from vital records (AR [2000-2011], GA [2001-2011], IA, 
MA, NC, NJ, UT) or from birth hospital records (AR [1997-2000], CA, GA [1998-2001], 
NY, TX). Each Center interviewed mothers of approximately 100 control infants each year. 
A woman was not eligible to participate in the NBDPS if she already participated with a 
previous pregnancy, could not complete the interview in English or Spanish, was 
incarcerated, or did not have legal custody of the child at the time of the interview. Due to 
state-specific requirements for obtaining informed consent from those who were less than 18 
years old at the end of their pregnancy, 3 of 10 Centers did not include eligible women less 
than 18 years old at the time of interview.
Study coordination
The NBDPS was managed by staff of the Birth Defects Branch at CDC's National Center on 
Birth Defects and Developmental Disabilities. The study-wide principal investigator, project 
officer, study coordinator, biologics coordinator, Georgia principal investigator, and data 
managers were part of the CDC management team. A Coordinating Council, established in 
2004, consisted of principal investigators from participating Centers; each Center had one 
vote. The Coordinating Council's charge was to oversee infrastructure, address managerial 
issues, and establish research priorities. The Coordinating Council communicated through 
monthly conference calls and an annual in-person meeting.
Several committees, comprised of individuals representing each Center, assisted with the 
coordination of NBDPS activities. The Clinicians Committee was composed of clinical 
geneticists who conducted case review and classification (described below). The 
Questionnaire and Methods Committee was responsible for ongoing quality control and 
improvements to the questionnaire and other aspects of the study protocol. The Interviewers 
and Study Coordinators Committee provided an opportunity for interviewers from different 
Centers to share their experiences and to be guided by peers and CDC staff on how to handle 
unique interviewing situations. The Biologics Committee, Epidemiologists/Analysts 
Committee, and the Data Sharing Committee have on-going activities even after the 
completion of data collection. The Biologics Committee continues to oversee the storage 
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and retrieval of biological specimens. The latter two committees are described in detail 
below.
Clinical NBDPS data: Case classification
For major structural birth defects included in the NBDPS (Table 1), all clinical information 
was reviewed by a clinical geneticist to confirm eligibility prior to requesting an interview. 
Because the goal of the study was to identify unknown causes of birth defects, cases with 
defects of known etiology, such as single gene conditions or chromosomal abnormalities 
were excluded.
The methodology for case classification has been described previously (Rasmussen and 
others, 2003). Cases were classified as isolated, multiple, or complex. A case was 
considered isolated if there was only one major defect diagnosed, regardless of whether 
minor defects were also diagnosed. If two or more major defects were diagnosed and the 
defects were developmentally related to one another, then the pattern of defects represented 
a sequence and the case was classified as isolated. When two or more major defects were 
diagnosed in the same organ system, the case was usually classified as isolated, with the 
exception being defects of the gastrointestinal tract. If two or more major defects occurred in 
different organ systems and the defects did not represent a sequence or a complex case, the 
case was classified as multiple. A complex case was defined as a pattern of major defects 
that are embryologically related and likely represent an early problem in morphogenesis, 
often akin to a developmental field defect. The causes of defects that are part of a complex 
case are generally not known, whereas patterns of defects that occur in sequences more often 
have a suspected cause (Table 2).
Some birth defect phenotypes were classified by the same clinical geneticist for all cases for 
the entire study period. For other defect types, classification was completed by more than 
one person, but the clinical geneticists developed guidelines that detailed the (1) inclusion 
and exclusion criteria for each defect eligible for the NBDPS; (2) rationale for including 
certain diagnostic codes for defects and related defects; (3) instructions and rationale for 
designating the final case classification (isolated, multiple, complex); and (4) instructions 
and recommendations to analysts on how the defect type could be analyzed in epidemiologic 
studies. For cases of congenital heart defects, four clinicians with expertise in pediatric 
cardiology and clinical genetics developed a classification of just the heart defects (Botto 
and others, 2007), and this classification was in addition to the classification of the overall 
constellation of defects that was completed by the clinical geneticists. Eligibility criteria for 
most defects were consistent over the study period, but for certain defects the criteria for 
inclusion in analyses changed (Table 3).
Causative genetic factors for some defects studied in NBDPS have been identified during 
the course of the NBDPS, necessitating changes in eligibility criteria. For instance, initially, 
the cause of CHARGE syndrome was not certain, and it was classified as an association (a 
group of anomalies that occur with a statistical clustering, but not representing a 
recognizable syndrome, sequence, or developmental field defect). Therefore, cases of 
potential CHARGE association having at least one NBDPS-eligible defect (e.g., choanal 
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atresia, heart defect) were included. Later, CHD7 mutations were identified as causative for 
some cases of CHARGE syndrome (Vissers and others, 2004). Therefore, cases with the 
phenotype of CHARGE syndrome with EDDs prior to January 1, 2006 remained in the 
study, but cases with EDDs after January 1, 2006 that had a CHD7 mutation were excluded. 
Cases with CHARGE syndrome phenotype that had no CHD7 mutation identified or did not 
have mutation testing performed were included throughout the study.
Another area of technological development that impacted NBDPS case classification was 
the comparative genomic hybridization (CGH) microarray, used to identify submicroscopic 
gains or losses of chromosomal material. Because these microduplications or microdeletions 
are potentially causative for birth defects, eligibility criteria based on a consensus statement 
(Miller and others, 2010) were developed for cases of duplication or deletion identified by 
CGH microarray with EDDs on or after January 1, 2009. If a phenotypically normal parent 
had the identical microduplication or microdeletion, then the infant's defect was presumed to 
represent a benign copy number variant, and the case infant was included in the study. If 
neither parent had the microduplication or microdeletion, then the chromosomal anomaly 
was presumed to be de novo and potentially pathogenic, so the case was excluded. However, 
if parental studies were not performed, then the case was excluded from the study if at least 
one of the following criteria was met for the microduplication or microdeletion: (1) it was 
associated with a previously characterized phenotype; (2) it contained at least one gene 
known or strongly suspected to be dosage sensitive; or (3) it was >400 kb in size. If none of 
these 3 criteria was met for the microduplication or microdeletion, the case was included.
Interview recruitment
Contact information for women eligible for study participation could be obtained from three 
sources: the Center's birth defects surveillance program, hospital records, or state birth 
certificates. Individual Centers sent out the introductory packet 6 weeks or more after the 
EDD; interviews had to be initiated by 24 months after the EDD. The introductory packet 
contained a letter introducing the study, which was signed by the local principal investigator, 
a calendar to assist women in accurately reporting exposures relative to their timing during 
her pregnancy, a “Frequently Asked Questions” document, and a “Rights of Human 
Subjects” document and a twenty dollar incentive. Materials were developed in 
collaboration with all Centers to ensure that the same information was delivered in the same 
way, although modifications for locally relevant information were allowed when required by 
the local Institutional Review Board (IRB). All protocols, contact materials and the 
interview content were approved by the CDC IRB, the Office of Management and Budget 
(OMB), and the local IRB(s) for each Center. The contents of the introductory packet and 
other study materials and products underwent several improvements over the study period in 
an effort to update and unify the appearance of all NBDPS materials; consistent graphical 
elements and color schemes were developed to increase study recognition and to facilitate 
higher participation (online-only Figure B).
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Overall, of the women who were invited to participate, 67% of cases and 65% of controls 
decided to take part. Interviews were conducted at each of the sites, or through a contractor, 
and participation has varied over time and by Center. Over the course of the study, use of 
telephone landlines decreased while use of cell phones increased; cell phone numbers were 
not always available through traditional directories. Centers adapted to challenges in 
recruitment in a variety of ways, including the use of cell phones instead of landlines to 
initiate calls (in order to match the participant's cellular provider to avoid call charges) and 
e-mail to contact study participants. In an effort to understand the magnitude of potential 
selection bias due to nonresponse, Cogswell and colleagues (Cogswell and others, 2009) 
compared demographic characteristics of controls who participated (n=4,495) to all eligible 
controls (n=6,681), and to all live born infants in the base population from which the 
controls were selected (n=2,468,697). Compared with base populations, control participants 
did not differ substantively in distributions of maternal or paternal age, number of previous 
live births, maternal smoking, or diabetes, but they did differ in other maternal 
characteristics (i.e., race/ethnicity, education, entry into prenatal care), and infant 
characteristics (i.e., birth weight, gestational age, and plurality). Compared with eligible 
controls who did not participate, control participants differed in distributions of maternal, 
but not infant, characteristics. Overall the authors concluded that control participants were 
generally representative of their base populations.
Interview Revisions
The computer-assisted telephone interview (CATI) was administered to women with 
pregnancies ending on or after October 1, 1997. The original CATI (Yoon and others, 2001) 
included questions on a range of topics (Table 4). Substantial changes to the CATI were 
implemented beginning with births on or after January 1, 2006.
Based on research suggesting that stressful life events may be associated with the occurrence 
of birth defects (Carmichael and others, 2007; de Weerth and Buitelaar, 2005; Hansen and 
others, 2000), a new section was added to the CATI that asked mothers about stressful life 
events immediately before and during pregnancy, as well as the availability of social 
support. The caffeine questions were changed to account for early pregnancy changes in 
intake and to estimate portion size. Established associations of maternal diabetes and obesity 
with increased risk for birth defects (Correa and others, 2008; Waller and others, 2007) 
prompted the addition of questions regarding fat consumption, dieting behavior, changes in 
weight, more detailed questions regarding diabetes management, and, in 2010, the addition 
of physical activity questions. In an effort to limit the interview to one hour, when new 
questions were added in 2006, other questions were removed. Specifically, questions about 
prenatal diagnoses, paternal drug use, and maternal assessment of occupational exposure to 
specific chemicals were excluded. A section on water use and consumption was significantly 
shortened, and combined with questions on use of a hot tub, Jacuzzi, or sauna.
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To better understand the role that genetic and epigenetic factors play in the etiologies of 
birth defects, cytobrushes were used to collect buccal (cheek) cell samples from NBDPS 
family triads (case- and control-infants and their parents). Following the completion of the 
interview, women were mailed a buccal cell collection kit that included collection 
instructions, documents for informed consent, six cytobrushes (two each for the mother, the 
child (if living), and the father), and a postage-paid return mailer. A monetary incentive ($20 
money order or check) was added to each kit beginning in 1999 or 2000, depending on the 
Center. In 2002, the kits were redesigned to provide better clarity, organization, and 
convenience (Online Figure B). Buccal cell collection kits were returned by 19,065 case 
families and by 6,211 control families (65% and 59% of those who received the kits, 
respectively).
Participation in buccal cell collection
In 2002, two Centers with low buccal cell collection participation began sending families an 
additional $20 incentive following the return of completed buccal cell collection kits, which 
resulted in increased participation. The success of the additional incentive led to its 
implementation by all Centers by 2008. Addition of the third incentive was particularly 
beneficial at Centers with the lowest participation, especially among some racial-ethnic 
groups, and participation across Centers increased by an average of 13 and 11 percentage 
points in case and control families, respectively.
To assess women's attitudes toward participation in buccal cell collection, six focus group 
discussions were held in September 2007 with women residing in metropolitan Atlanta, 
Georgia who had completed the NBDPS interview and either did or did not complete buccal 
cell collection (Jenkins and others, 2009; Jenkins and others, 2011). Four of the focus groups 
were comprised solely of non-Hispanic black women because they were the racial-ethnic 
group with the lowest participation. Barriers to participation reported by focus group 
participants included concerns about how they were identified, government involvement, 
potential misuse of the DNA specimens, not disclosing individual genetic results, sterility of 
cytobrushes sent through the mail, and paternal skepticism. Motivations for participation 
included having a child affected by a birth defect, researcher credibility, non-invasive 
collection methods, monetary incentives, professional-style study materials, and positive 
experiences with study interviewers. To address some of the barriers, NBDPS study 
materials were updated with information about how infants were identified, and a website 
was developed that included a video of buccal cell collection and information on the use, 
storage, and disposal of DNA specimens. To alleviate concerns over cytobrush sterility, 
“Sterile if package is unopened” was added to the cytobrush packaging.
Glidewell and colleagues (Glidewell and others, 2013) examined factors associated with 
participation in buccal cell collection in the NBDPS. Buccal responders were more likely to 
be non-Hispanic white, older case mothers with higher education, higher household 
incomes, pregnancies that were intended, to have had a shorter interval between their EDD 
and interview date, to have received a redesigned buccal cell collection kit and an additional 
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$20 incentive, to have consumed folic acid and not to have smoked cigarettes during the 
periconceptional period.
Buccal cell specimen quality
In response to concerns about DNA degradation during transit, cytobrushes packaged in 
closed plastic containers were replaced with cytobrushes packaged in paper-backed peel 
pouches in mid-2003. The impact of cytobrush packaging on the yield and quality of self-
collected buccal cell-derived DNA was assessed (Gallagher and others, 2011; Krakowiak 
and others, 2003). Higher median human-specific DNA yields (1300ng vs. 60ng) and more 
successful short tandem repeat (STR) amplification rates (99.5% vs 59.5%) were observed 
when DNA was extracted from cytobrushes transported in the new pouches that allowed air-
drying when compared to DNA extracted from cytobrushes transported in closed plastic 
containers.
To further improve DNA specimen quantity and quality, some families who previously 
submitted closed container cytobrushes were asked in 2006-2008 to collect new specimens 
using cytobrushes packaged in paper-backed peel pouches. Eligible families had pregnancies 
affected by spina bifida, gastroschisis, or longitudinal limb defects; and an equal number of 
control families were also invited. Return rates (families who returned kits /eligible families) 
varied by Center and case-control status (20%–83% for cases; 13%–63% for controls).
Centralized DNA processing laboratory
When DNA collection via cytobrushes was initially integrated into the NBDPS, DNA was 
extracted at each Center using different methods, and short tandem repeat (STR) markers 
were amplified using two sets of primer pairs (Figure 3). Quality control (QC) criteria 
included successful polymerase chain reaction (PCR) amplification after at least two 
attempts with at least one STR marker and alleles consistent with the reported family 
relationship. If those standards were met, DNA extracted from one cytobrush was divided 
into 10 or 20 aliquots of equal size and the aliquots were shipped to the central 
biorepository. DNA from the second cytobrush was retained at the local Center. In 2003, a 
centralized laboratory was established at the CDC to improve consistency and standardize 
extraction and QC methods (Figure 3). One cytobrush from each NBDPS participant was 
retained at the local Center, but the second cytobrush was sent to the centralized laboratory 
at CDC for DNA extraction using either a phenol-chloroform method (Garcia-Closas and 
others, 2001) or Gentra Puregene® (QIAGEN®); human genomic DNA (gDNA) yields were 
assessed by quantitative real-time PCR using the human RNaseP gene, and three or four 
STR markers were used to assess DNA quality. DNA specimens that met QC criteria 
(human gDNA concentration ≥0.1 ng/μl, successful PCR amplification after at least two 
attempts with at least one STR marker, and alleles consistent with the reported family 
relationship) were divided into two aliquots of equal size and shipped to the central 
biorepository. Both before and after establishment of the centralized lab, if a specimen did 
not meet QC criteria, the family was contacted and asked to provide additional specimens; 
however, due to low return rates and lack of resolution of the initial inconsistencies with 
recollected specimens, as of 2005, families whose alleles were not consistent with the 
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reported family relationship (i.e. non-paternity) were not asked to provide additional 
specimens.
External genotyping quality assessment
To ensure proficiency of laboratories genotyping NBDPS buccal-derived DNA specimens 
independent of source material, NBDPS genotyping laboratories annually genotyped a 
standard single nucleotide polymorphism (SNP) set on a subset of the Coriell Institute for 
Medical Research's Polymorphism Discovery Resource (PDR) DNA specimens (Collins and 
others, 1998). The SNP set was determined by the NBDPS Genetic Analysis Working 
Group and included SNPs assayed by multiple labs and at least one SNP with publicly 
available genotypes. Standard 96-well plates that include 86 PDR specimens, four replicates, 
two negative controls, and four empty wells for internal laboratory genotyping controls were 
plated by Coriell and sent directly to each NBDPS laboratory. Plate formats and content 
were changed yearly. Laboratories were blinded to specimen type and reported genotyping 
results centrally to the CDC for analysis. After implementation of annual external quality 
assessment (EQA), call rates of 97-100% were reported across NBDPS laboratories. 
Concordance of 99-100% was reported between NBDPS laboratories and between NBDPS 
laboratories and the publicly available genotypes.
To assure data quality across laboratories using arrays from higher throughput platforms, 
NBDPS genotyping laboratories ran assays on a set of paired cytobrush buccal- and whole 
blood-derived DNA samples from 6 parent-offspring trios ascertained through the 
University of Washington under an IRB-approved protocol, prior to implementation of each 
new project. Laboratories planning to use whole genome amplified (WGA) products were 
required to run assays using paired gDNA and WGA products. After implementation of 
annual EQA, call rates of 92-100% were reported across NBDPS genotyping laboratories. 
Concordance between paired blood-buccal samples was 100% pre- and post-WGA. Inter-
laboratory concordance for variants assayed in common was 100%. Additionally, SNP 
genotyping was consistent with Mendelian inheritance.
Data management
NBDPS data were stored in three major database types: the clinical databases, containing the 
abstracted case data; the CATI databases; and the biologic sample databases. Centers 
transferred data to CDC monthly to ensure the central databases were current, and to reduce 
the chance of substantial data loss in case of database corruption. Each Center first deposited 
all three current databases on CDC's secure data network; then CDC programmers added 
any new data to the central databases and then placed updated files for each Center in their 
private folder on the secure data network.
Analysis of NBDPS data is on-going. Data are accessible to NBDPS collaborators through 
the Data Analysis Tools (DAT), a Microsoft Access database. The DAT is a centralized 
effort that serves to improve data quality and efficiency of analyses conducted by 
investigators in different Centers. The DAT enables NBDPS analysts in all Centers to create 
datasets that contain only those variables that will be used for an approved project. The DAT 
includes a data dictionary, which provides variable names, definitions, and formatting 
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information. The DAT contains a set of calculated variables created by combining several 
interview questions, including maternal age at delivery, maternal body mass index, 
indicators for whether the mother used alcohol or cigarettes during the periconceptional 
period, maternal diabetes status, and use of folic acid supplements. The DAT does not 
contain any names, addresses or geocodes. A specific tool using the medication database 
from the Slone Epidemiology Center at Boston University allows analysts to create exposure 
variables for specific medications or all medications with a specific component, and to 
define the exposure period of interest for that medication. Data from the food frequency 
section, which pertained to the year before pregnancy, was used in combination with data 
from the United States Department of Agriculture to assign levels of nutrient and calorie 
intake with the assistance of North Carolina Department of Nutrition Clinical Research 
Center, Nutrition Epidemiology Core. Analysts communicate through monthly conference 
calls of the Epidemiologists/Analysts Committee, a listserv and a SharePoint site. And, as a 
quality control measure, each analysis is replicated by an independent analyst prior to 
submission for publication.
The Data Sharing Committee for NBDPS has two major responsibilities: the ongoing task of 
deciding how data will be equitably shared for analysis and providing abstract and 
manuscript review prior to submission to scientific meetings or journals. This committee 
consists of principal investigators or co-investigators from each Center. Obtaining approval 
to conduct an NBDPS analysis is a two-step process. First, a two-page letter of intent is 
submitted containing scientific background/justification, a brief summary of the analytical 
plan and any conflicts with existing NBDPS analytic projects. Upon approval by the 
Committee, the lead investigator then submits a more detailed proposal. The proposal must 
contain a detailed analytical plan, including power calculations. The Committee requires 
annual updates from the lead investigator on the progress of each project. As of December 
2014, there were more than 520 proposed projects. Senior investigators are requested to 
serve as NBDPS data sharing editor for six-month periods of time, where they coordinate 
the anonymous review of all NBDPS manuscripts. Review of abstracts to be submitted to 
scientific meetings is coordinated at the CDC.
Investigators from outside NBDPS who are interested in analyzing NBDPS data must 
collaborate with one of the NBDPS principal investigators, or they can write a letter to the 
Data Sharing Committee describing their research interest. The committee will let the 
researcher know if their interest is already covered under an existing proposed project or 
will forward it to NBDPS researchers interested in that topic in order to establish a formal 
collaboration. Collaboration with external investigators in this manner is encouraged.
Expanded occupational and environmental data
Through an agreement with the CDC's National Institute for Occupational Safety and Health 
(NIOSH), industrial hygienist contractors at Battelle and occupational epidemiologists at the 
NIOSH have used the responses to the maternal occupation sections of the NBDPS CATI to 
create an occupational exposure database. The database includes the estimated frequency, 
intensity, and duration of job exposures for over 10,000 respondents. The occupational team 
estimated quantified exposure to occupational chemicals including pesticides, chlorinated 
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and aromatic solvents, polycyclic aromatic hydrocarbons, and heavy metals, resulting in 
several publications ((Kielb and others, 2014; Lupo and others, 2012; Rocheleau and others, 
2011)).
Combining residential locations with other geographic data may inform environmental 
exposures such as air pollution. Therefore the NBDPS questionnaire included a complete 
residential history, from three months before conception through the date of delivery. 
Women were asked to report, to the best of their ability, the exact street address of each 
residence. To ensure the application of a uniform data cleaning and geocoding method, CDC 
requested that all NBDPS residential address data be centrally geocoded by the Agency for 
Toxic Substances and Disease Registry's Geographic Research, Analysis and Services 
Program. To protect participant privacy, CDC returned geocoded address data to the 
respective Centers, but this data can be requested for specific projects (Stingone and others, 
2014).
Limitations of NBDPS
There were several limitations of the NBDPS. The first is that, on average only about two-
thirds of invited women participated, which could potentially introduce selection bias if 
nonparticipants had substantially different risk profiles from those who participated. NBDPS 
control participants were older, more often non-Hispanic white and more highly educated 
than non-participants (Cogswell and others, 2009). The fact that the inclusion of stillbirths 
and induced abortions changed over the data collection period is a limitation, as is the to-be-
expected difference in participation based on the pregnancy outcome. Another limitation 
was that exposure information was self-reported. Recall of the timing and duration of 
exposures occurring up to 2 years in the past was challenging for some participants, 
especially for items requiring detailed information. Recall of use of over-the-counter and 
prescription medications during early pregnancy, is of particular concern. To optimize 
recall, women were first asked about specific diseases or medical conditions and then asked 
about medication use to treat conditions. In addition, women were asked about specific 
medications using a list of specific medication names, without reference to diseases or 
conditions. However, NBDPS did not capture information on medication dose, and for those 
medications that were reported in response to the medication list, there was no information 
about the indication for use. For some exposures, validation studies were conducted. One 
such project compared fertility treatment data reported by assisted reproductive technology 
clinics to NBDPS participants’ responses to questions about fertility treatment use 
(Liberman and others, 2014). Using the clinic data as the gold standard, the sensitivity of 
maternal report for use of in vitro fertilization (IVF) was 91%. Another validation study 
compared responses to CATI questionnaire items regarding smoking to data on birth 
certificates; smoking was more often reported in the NBDPS (Srisukhumbowornchai and 
others, 2012). Another study conducted a Bayesian bias analysis which incorporated 
previous research on reliability of self-reported smoking to examine the relationship of 
smoking and orofacial clefts reported from the NBDPS (Honein and others, 2007; 
MacLehose and others, 2009). Smoking recall bias has been raised as a concern in previous 
studies looking at the smoking-orofacial cleft association. After correcting for potential 
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misclassification using bias modeling, this study found the likely levels of bias did not 
impact the relationship between smoking and orofacial clefts in NBDPS.
Lessons learned
The NBDPS has provided an unprecedented level of information for studying birth defects 
and for learning best practices for future birth defects research. A major strength of the 
study, in addition to its sample size, was the successful collaboration with multi-disciplinary 
teams across 10 Centers in the United States. Consistency of study methods across the sites, 
particularly use of the same case inclusion criteria and interview instrument allowed for the 
creation of a pooled dataset for analysis that is both large and internally consistent. Multiple 
levels of case review including a study-wide central review ensured consistency in 
determining case eligibility and classification. Providing centralized data management with 
monthly replication safe-guarded the data. One particularly beneficial lesson learned 
regarding buccal cell DNA collection was letting brushes air dry, which resulted in higher 
DNA yields and better quality DNA. A last key step in fostering this collaboration was 
establishing clear data sharing guidelines. Clear rationale for undertaking a project as well as 
critical feedback at the start of projects resulted in a more efficient review process and 
higher quality manuscripts.
The NBDPS has moved the field of birth defects epidemiology forward since its launch in 
1996. Over 44,000 women with pregnancies in 1997-2011 participated in the study. To date, 
more than 350 interdisciplinary researchers have collaborated on more than 200 peer-
reviewed manuscripts. The study has provided training opportunities where many masters-
level students have learned about reproductive epidemiology working on NBDPS analyses 
and at least six doctoral dissertations have been completed using NBDPS data. And this is 
only the beginning. Papers on genetic risk factors for birth defects are beginning to be 
published using data from the NBDPS – and there are many more genetic, environmental, 
and gene-environment interaction analyses being planned. NBDPS will be a rich source of 
epidemiological and genetic data to study risk factors for birth defects for many years to 
come.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Basic study process for the National Birth Defects Prevention Study (NBDPS)
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Inclusion of cases among live births, stillbirths and induced abortions, and data sources used 
specifically to ascertain prenatal diagnoses, by estimated year of delivery and Center.
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Comparison of DNA extraction and quality control completed at each Center (pre-
centralized DNA processing lab) and at the centralized DNA processing lab on samples that 
were sent to the repository.
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Table 4
Computer-assisted telephone interview (CATI) sections in the order they were asked for the periods 
1997-2005 and 2006-2011
CATI 1997-2005 CATI 2006-2011
Index pregnancy Index pregnancy
    Previous pregnancies
    Addresses during pregnancy
    Contraception
    Prenatal care
    Fertility treatments - mother
    Fertility treatments - father
    Morning sickness
    Diarrhea
    Dieting
    Weight gain/loss during pregnancy
Maternal health Maternal health
Pregnancy history Medication
    Previous pregnancies
    Weight gain/loss
    Contraception
    Fertility treatments - father
    Fertility treatments - mother
    Morning sickness
    Morning sickness weight loss
    Prenatal care
    Medication
Vitamins Vitamins




Home environment Substance abuse
    Addresses during pregnancy         Reduced questions about father
    Hot tub/sauna use
Mother's occupation Water use (reduced)
Father's occupation Mother's occupation
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CATI 1997-2005 CATI 2006-2011
Family demographics - mother Father's occupation
Family demographics - father Physical activity
        (added for interviews after 10/1/2010)
Home water environment Family demographics - mother
Drinking water at home Family demographics - father
Drinking water at work/school Family information - mother and father
Home water use Closing/debriefing
Swimming pool use
Closing/debriefing
Note: A PDF of the most recent version of each of these two CATIs is available upon request from the corresponding author.
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